Ibgliptin-M 500 Tablet SR is a combination oral antidiabetic medication containing Metformin 500 mg and Teneligliptin 20 mg, designed for sustained release to optimize glycemic control in patients with type 2 diabetes mellitus. Metformin, a biguanide, primarily reduces hepatic glucose production and improves peripheral insulin sensitivity, thereby enhancing glucose uptake and utilization. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The sustained-release formulation of Ibgliptin-M 500 ensures a gradual and prolonged drug release, contributing to improved patient compliance and stable plasma drug concentrations. This combination therapy is indicated for patients inadequately controlled on diet and exercise alone or those requiring dual therapy to achieve target glycemic levels. Ibgliptin-M 500 should be used with caution in patients with renal or hepatic impairment and is contraindicated in cases of diabetic ketoacidosis or severe renal dysfunction. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort. Regular monitoring of blood glucose, renal function, and potential adverse reactions is recommended to ensure therapeutic efficacy and safety. This combination offers a complementary mechanism of action for effective management of hyperglycemia in type 2 diabetes.